Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 1/20 | 0.64 |
| ▸ | ACHE | P22303 | 9/20 | 0.62 |
| ▸ | BACE1 | P56817 | 9/20 | 0.62 |
| ▸ | BCHE | P06276 | 7/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.55 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.55 |
| ▸ | FABP6 | P51161 | 1/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.54 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.50 |
| ▸ | EBP | Q15125 | 1/20 | 0.50 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4080791 | 0.94 | FABP6 (0.60) | DRD4ACHEBACE1BCHEMEN1 | |
| SCHEMBL16269315 | 0.91 | ACHE (0.60) | DRD4ACHEBACE1BCHEMEN1 | |
| SCHEMBL1189971 | 0.91 | ACHE (0.60) | DRD4ACHEBACE1BCHEMEN1 | |
| SCHEMBL29238649 | 0.88 | DRD4 (0.61) | DRD4ACHEBACE1BCHEMEN1 | |
| SCHEMBL3712791 | 0.86 | ACHE (0.60) | DRD4ACHEBACE1BCHEMEN1 | |
| SCHEMBL16795397 | 0.86 | DRD4 (0.53) | DRD4ACHEBACE1BCHECARM1 | |
| SCHEMBL18640371 | 0.85 | EPHX2 (0.60) | DRD4ACHEBACE1BCHEMEN1 | |
| SCHEMBL6418433 | 0.85 | DRD4 (0.56) | DRD4ACHEBACE1BCHEMEN1 | |
| SCHEMBL12803076 | 0.84 | CARM1 (0.59) | DRD4ACHEBACE1BCHEKMT2A | |
| SCHEMBL18640333 | 0.84 | TEAD1 (0.71) | DRD4ACHEBACE1BCHEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4132944-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | Cocrystal Pharma, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| US-11116757-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-09-14 | — | — | US | disclosed |
| US-20210069172-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-03-11 | — | — | US | disclosed |
| US-20180256558-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2018-09-13 | — | — | US | disclosed |
| CN-105859639-A | NOVEL ANTI-INFLAMMATORY AGENTS | 雷斯韦洛吉克斯公司 | 2016-08-17 | — | — | CN | disclosed |
| WO-2013175281-A1 | USE OF SUBSTITUTED 2-PHENYL-3H-QUINAZOLIN-4-ONES AND ANALOGS FOR INHIBITING BROMODOMAIN AND EXTRA TERMINAL DOMAIN (BET) PROTEINS | RVX THERAPEUTICS INC. (CA) | 2013-11-28 | — | — | WO | disclosed |
| CN-102427813-A | Novel anti-inflammatory agents | RESVERLOGIX CORP | 2012-04-25 | — | — | CN | disclosed |
| EP-2408454-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010106436-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2010-09-23 | — | — | WO | disclosed |
| EP-2102171-A1 | NEW PYRIDAZINE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2009-09-23 | — | — | EP | disclosed |
| EP-1960359-A1 | NOVEL N-SULFAMOYL-PIPERIDINEAMIDES FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY AND RELATED CONDITIONS | Solvay Pharmaceuticals GmbH (DE) | 2008-08-27 | — | — | EP | disclosed |
| WO-2008071646-A1 | NEW PYRIDAZINE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-06-19 | — | — | WO | disclosed |
| EP-1844037-A1 | CHEMICAL COMPOUNDS | Pfizer Limited (GB) | 2007-10-17 | — | — | EP | disclosed |
| CN-1326519-C | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK AS (DK) | 2007-07-18 | — | — | CN | disclosed |
| WO-2007065948-A1 | NOVEL N-SULFAMOYL-PIPERIDINEAMIDES FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY AND RELATED CONDITIONS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-06-14 | — | — | WO | disclosed |
| CN-1293065-C | Piperazinyl- or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase | NOVARTIS AG (CH) | 2007-01-03 | — | — | CN | disclosed |
| WO-2006077499-A1 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| CN-1646509-A | Piperazinyl-or piperidinylamine-sulfamic acid amides as steroid sulfatase inhibitors | NOVARTIS AG (CH) | 2005-07-27 | — | — | CN | disclosed |
| CN-1602191-A | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK AS (DK) | 2005-03-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180256558-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | UBQLN1, CUL1, DCUN1D1 | DRD4 2929/4885ACHE 3169/4885BACE1 2234/4885 |
| US-11116757-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | UBQLN1, CUL1, DCUN1D1 | DRD4 2929/4885ACHE 3169/4885BACE1 2234/4885 |
| US-20210069172-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | UBQLN1, CUL1, DCUN1D1 | DRD4 2929/4885ACHE 3169/4885BACE1 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.